LSBio (www.lsbio.com) enables researchers by providing a variety of antibodies and research reagents. Previous acquisitions of Nordic-MUbio and Everest Biotech have strengthened the company's offering of proprietary monoclonal and polyclonal antibodies. The continued emphasis for LSBio has been on building the portfolio and coupling that with application-specific antibody validation. Through ongoing in-house testing, over 15,000 of the LSBio antibodies have been identified as exceptional IHC reagents and given the IHC-plus™ brand. LSBio itself was acquired by Thompson Street Capital Partners (TSCP) in 2018.
Looking for a particular LSBio employee's phone or email?
The LSBio annual revenue was $7.5 million in 2026.
LSBio is based in Seattle, Washington.
The NAICS codes for LSBio are [5417, 541714, 54, 541, 54171].
The SIC codes for LSBio are [87, 873].